Therapeutic drug monitoring of imatinib: Bayesian and alternative methods to predict trough levels. - Wikidata - awgldk - TriplyDB

Therapeutic drug monitoring of imatinib: Bayesian and alternative methods to predict trough levels.

Therapeutic drug monitoring of imatinib: Bayesian and alternative methods to predict trough levels.

http://www.wikidata.org/entity/Q39651800

about

Simple methodology for the therapeutic drug monitoring of the tyrosine kinase inhibitors dasatinib and imatinib.A Multiagent System for Dynamic Data Aggregation in Medical Research.Effect of Kidney Function on Drug Kinetics and Dosing in Neonates, Infants, and Children Comparative pharmacokinetic evaluation and bioequivalence study of three different formulations of Imatinib Mesylate in CML patients Clinical implications of repeated drug monitoring of imatinib in patients with metastatic gastrointestinal stromal tumour.Benchmarking therapeutic drug monitoring software: a review of available computer tools.Clinical Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies Approved to Treat Rheumatoid Arthritis.Guidance to develop individual dose recommendations for patients on chronic hemodialysis.Association of the hOCT1/ABCB1 genotype with efficacy and tolerability of imatinib in patients affected by chronic myeloid leukemia.Clinical usefulness of therapeutic concentration monitoring for imatinib dosage individualization: results from a randomized controlled trial.Development of a Pharmacokinetic Model to Describe the Complex Pharmacokinetics of Pazopanib in Cancer Patients.Integrated semi-physiological pharmacokinetic model for both sunitinib and its active metabolite SU12662.Individualized Dosing Algorithms and Therapeutic Monitoring for Antiepileptic Drugs.How 'Optimal' are Optimal Sampling Times for Tyrosine Kinase Inhibitors in Cancer? Practical Considerations.Population pharmacokinetics of imatinib in Iranian patients with chronic-phase chronic myeloid leukemia.

P2860

Q34377463-3233298A-CACF-4AB9-B88D-EEB4227A171B Q36224268-3A79CFBA-A894-48D8-87DE-228222963811 Q36322918-2879EF46-9C64-4082-84B3-88B752C6A45A Q36566250-C8470907-72AD-4417-ADCB-E2043DC2EB50 Q37504935-2DF04567-3620-4F6A-B59E-D75D877D8D31 Q38063750-B60A6202-17D2-4C84-BA44-E771B54DC665 Q38540353-8D5BCCC4-A30C-46D0-84FF-49E5107ECE04 Q38817612-3A86351F-AE11-4D23-A52A-D79758169CCB Q38910072-6E3B3C48-D84E-4828-985C-97C8740D075B Q39116591-3E34B609-5524-4A03-B412-41F4B27CF7EA Q39480956-3CCE77B1-B297-4604-A6EF-C43B0CB39615 Q40126912-03822517-8F9A-4A8C-9418-076C39198B61 Q47786666-F5DA7517-2C93-4BD0-A6B0-03B9A2A8B5EB Q48826707-DB4788B3-1BE5-43E6-8087-F694A90DBC13 Q51088241-7269F788-3998-41F8-91AF-2262595C904B

P2860

Therapeutic drug monitoring of imatinib: Bayesian and alternative methods to predict trough levels.

http://www.wikidata.org/entity/Q39651800

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Therapeutic drug monitoring of ...... hods to predict trough levels.

@en

Therapeutic drug monitoring of ...... hods to predict trough levels.

@nl

type

label

Therapeutic drug monitoring of ...... hods to predict trough levels.

@en

Therapeutic drug monitoring of ...... hods to predict trough levels.

@nl

prefLabel

Therapeutic drug monitoring of ...... hods to predict trough levels.

@en

Therapeutic drug monitoring of ...... hods to predict trough levels.

@nl

P1433

Q39651800-4FBBF281-7CFA-4DDA-B138-C62600344205

P1476

Q39651800-B49EC26B-7FDA-420C-985C-6348C833E02C

P2093

Q39651800-0B68CE6B-1280-4CC7-8FF0-10F1E8FE3B4C

Q39651800-992BF61C-024D-4180-9371-7A4F942C4236

Q39651800-9B7AAEE0-C1EB-40EC-B56A-5964B6E6288B

Q39651800-C2066C6A-3FE0-4AFA-94FD-A4178407D705

P2860

Q39651800-0CE30D1B-89C7-4933-BE67-C148BD8BE399

Q39651800-124585D0-1147-4218-B443-94C771AE50AE

Q39651800-1355A97E-3A3E-4F28-B3AC-372BF3D36BBF

Q39651800-143E04E5-DCE5-4E7D-818F-3CB9B5DDD528

Q39651800-16054261-C482-4F63-AD70-4D1504D4A07E

Q39651800-1B9E691C-63F5-4CE6-A178-D2268C605001

Q39651800-35FF2A56-84C2-49EC-8F5B-674CD698075B

Q39651800-379B96F8-51FD-414C-85A7-95BDC63DFA9D

Q39651800-46E586D2-5A0F-4F11-83FB-102ADA970662

Q39651800-4AE61A35-AA8B-423E-8D98-D423BCB7C598

P2888

Q39651800-59A4D756-843F-49A9-9C81-ECE0CB07C002

P304

Q39651800-B6B3EE5C-DA32-4402-841B-9FF1559CD2AF

P31

Q39651800-1FCB78D1-AAB1-46F4-86B3-7E068D06177B

P356

Q39651800-8E0EE0B7-1268-4B49-AD07-82EB531B95A3

P433

Q39651800-E93F3CC1-BAC3-4E8E-8339-0CF75C2F51E8

P478

Q39651800-674FB531-100F-4402-9455-04FFE07BE22F

P50

Q39651800-07C1733B-87A6-4426-8E7F-A787AD6D71B1

Q39651800-1DFA3A31-5F56-47AE-94BD-B75E0949BAD8

Q39651800-7F97C0EF-BE6E-4F17-B28B-2CF77A6383AC

Q39651800-98614AA6-5E63-416F-9211-D995907F0979

P577

Q39651800-D85B1E35-B6C1-4E95-B6BC-53749E8D42AF

P6179

Q39651800-9AD640EF-EFAC-451A-B443-2CA2E738B137

P698

Q39651800-21303477-EDEB-42D1-A347-158098DEE1ED

P356

11596990-000000000-00000

P1433

Clinical Pharmacokinetics

P1476

Therapeutic drug monitoring of ...... thods to predict trough levels

@en

P2093

Amina Haouala

http://www.w3.org/2001/XMLSchema#string

Michael Montemurro

http://www.w3.org/2001/XMLSchema#string

Serge Leyvraz

http://www.w3.org/2001/XMLSchema#string

Thierry Buclin

http://www.w3.org/2001/XMLSchema#string

P2860

Forecasting individual pharmacokinetics

Imatinib front-line therapy is safe and effective in patients with chronic myelogenous leukemia with pre-existing liver and/or renal dysfunction.

Adaptive control methods for the dose individualisation of anticancer agents.

NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors.

Imatinib and Panax ginseng: a potential interaction resulting in liver toxicity.

Individualised cancer chemotherapy: strategies and performance of prospective studies on therapeutic drug monitoring with dose adaptation: a review.

Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.

Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.

Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer.

Application of pharmacokinetic modelling to the routine therapeutic drug monitoring of anticancer drugs.

P2888

11596990-000000000-00000

P304

187-201

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2165/11596990-000000000-00000

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

51

http://www.w3.org/2001/XMLSchema#string

P50

Laurent Arthur Decosterd

P577

2012-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1006848965

http://www.w3.org/2001/XMLSchema#string

P698

22339450

http://www.w3.org/2001/XMLSchema#string